Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
- PMID: 16857819
- DOI: 10.1158/1078-0432.CCR-06-0087
Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
Abstract
Recent evidence indicates that high epidermal growth factor receptor (EGFR) gene copy number evaluated by fluorescence in situ hybridization is an excellent predictive biomarker for response and survival benefit in patients with non-small cell lung cancer who receive epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Data on EGFR protein expression by immunohistochemistry as a selection marker are conflicting, although several studies showed that the treatment benefit was confined to EGFR-positive patients. Our studies and others showed that fluorescence in situ hybridization and immunohistochemistry were associated with the best predictive value. Expeditious validation of this information in prospective clinical trials with patient selection to first-line treatment is currently being done or planned by several cancer research groups worldwide.
Similar articles
-
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. doi: 10.1158/1078-0432.CCR-07-0332. Clin Cancer Res. 2007. PMID: 17671150 Review.
-
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555. Clin Cancer Res. 2006. PMID: 16857820 Review.
-
EGFR FISH versus mutation: different tests, different end-points.Lung Cancer. 2008 May;60(2):160-5. doi: 10.1016/j.lungcan.2008.02.008. Epub 2008 Mar 25. Lung Cancer. 2008. PMID: 18367287 Review.
-
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.Oncogene. 2009 Aug;28 Suppl 1:S14-23. doi: 10.1038/onc.2009.197. Oncogene. 2009. PMID: 19680292 Review.
-
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.J Clin Oncol. 2008 Feb 20;26(6):983-94. doi: 10.1200/JCO.2007.12.9858. J Clin Oncol. 2008. PMID: 18281673 Review.
Cited by
-
Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.PLoS One. 2018 Apr 24;13(4):e0196350. doi: 10.1371/journal.pone.0196350. eCollection 2018. PLoS One. 2018. PMID: 29689091 Free PMC article.
-
Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.Curr Pharm Des. 2008;14(28):2983-98. doi: 10.2174/138161208786404326. Curr Pharm Des. 2008. PMID: 18991714 Free PMC article. Review.
-
Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.Med Oncol. 2010 Sep;27(3):853-60. doi: 10.1007/s12032-009-9296-7. Epub 2009 Sep 10. Med Oncol. 2010. PMID: 19763916
-
Meta-learning-based Inductive logistic matrix completion for prediction of kinase inhibitors.J Cheminform. 2024 Apr 16;16(1):44. doi: 10.1186/s13321-024-00838-9. J Cheminform. 2024. PMID: 38627866 Free PMC article.
-
Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.PLoS One. 2017 Jan 26;12(1):e0170187. doi: 10.1371/journal.pone.0170187. eCollection 2017. PLoS One. 2017. PMID: 28125617 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous